Breaking and Sealing Barriers in Retinal Gene Therapy

Affiliations

¹ Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Grousbeck Gene Therapy Center, Ocular Genomics Institute, Massachusetts Eye and Ear, Boston, MA, USA; Berman-Gund Laboratory for Retinal Degeneration, Massachusetts Eye and Ear, Boston, MA, USA. Electronic address: joan_miller@meei.harvard.edu.
² Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Grousbeck Gene Therapy Center, Ocular Genomics Institute, Massachusetts Eye and Ear, Boston, MA, USA; Berman-Gund Laboratory for Retinal Degeneration, Massachusetts Eye and Ear, Boston, MA, USA; The Broad Institute of Harvard and MIT, Cambridge, MA, USA. Electronic address: luk_vandenberghe@meei.harvard.edu.

Comment

Joan W Miller et al. Mol Ther. 2018.

. 2018 Sep 5;26(9):2081-2082.

doi: 10.1016/j.ymthe.2018.08.003. Epub 2018 Aug 11.

¹ Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Grousbeck Gene Therapy Center, Ocular Genomics Institute, Massachusetts Eye and Ear, Boston, MA, USA; Berman-Gund Laboratory for Retinal Degeneration, Massachusetts Eye and Ear, Boston, MA, USA. Electronic address: joan_miller@meei.harvard.edu.
² Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Grousbeck Gene Therapy Center, Ocular Genomics Institute, Massachusetts Eye and Ear, Boston, MA, USA; Berman-Gund Laboratory for Retinal Degeneration, Massachusetts Eye and Ear, Boston, MA, USA; The Broad Institute of Harvard and MIT, Cambridge, MA, USA. Electronic address: luk_vandenberghe@meei.harvard.edu.

No abstract available

Comment on

Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.
Cukras C, Wiley HE, Jeffrey BG, Sen HN, Turriff A, Zeng Y, Vijayasarathy C, Marangoni D, Ziccardi L, Kjellstrom S, Park TK, Hiriyanna S, Wright JF, Colosi P, Wu Z, Bush RA, Wei LL, Sieving PA. Cukras C, et al. Mol Ther. 2018 Sep 5;26(9):2282-2294. doi: 10.1016/j.ymthe.2018.05.025. Epub 2018 Jul 7. Mol Ther. 2018. PMID: 30196853 Free PMC article. Clinical Trial.

1. U.S. Food and Drug Administration. (2018). Luxturna. https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/a....
1. Russell S., Bennett J., Wellman J.A., Chung D.C., Yu Z.F., Tillman A., Wittes J., Pappas J., Elci O., McCague S. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–860. - PMC - PubMed
1. Cukras C., Wiley H.E., Jeffrey B.G., Sen H.N., Turriff A., Zeng Y., Vijayasarathy C., Marangoni D., Ziccardi L., Kjellstrom S. Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery. Mol Ther. 2018;26:2282–2294. this issue. - PMC - PubMed
1. Miller J.W. Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013;155:1–35.e13. - PubMed
1. Park T.K., Wu Z., Kjellstrom S., Zeng Y., Bush R.A., Sieving P.A., Colosi P. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther. 2009;16:916–926. - PMC - PubMed